Aprea Therapeutics Q2 2024 Update: Assets and Liabilities Detailed

TL;DR

**Aprea Therapeutics Q2 2024: $5.4M Assets, $3.7M Liabilities. Financials filed.**

AI Summary

Aprea Therapeutics, Inc. filed its 10-Q for the period ending June 30, 2024. The company reported total assets of $5.43 million and total liabilities of $3.74 million. The filing also details changes in its common stock and preferred stock, including activity related to at-market offerings during Q1 2023.

Why It Matters

This filing provides a snapshot of Aprea Therapeutics' financial health, including its asset and liability position, which is crucial for investors to assess the company's stability and operational capacity.

Risk Assessment

Risk Level: medium — The company's financial figures indicate a significant portion of liabilities relative to assets, suggesting potential financial strain.

Key Numbers

• $5.43M — Total Assets (As of June 30, 2024)
• $3.74M — Total Liabilities (As of June 30, 2024)

Key Players & Entities

• Aprea Therapeutics, Inc. (company) — Filer of the 10-Q
• 2024-06-30 (date) — End of reporting period
• $5.43 million (dollar_amount) — Total assets
• $3.74 million (dollar_amount) — Total liabilities

FAQ

Key Financial Figures

• $0.001 — h registered: Common stock, par value $0.001 per share APRE The NASDAQ Stock Mar

Filing Documents

• apre-20240630x10q.htm (10-Q) — 1414KB
• apre-20240630xex31d1.htm (EX-31.1) — 10KB
• apre-20240630xex31d2.htm (EX-31.2) — 10KB
• apre-20240630xex32d1.htm (EX-32.1) — 7KB
• apre-20240630xex32d2.htm (EX-32.2) — 7KB
• 0001558370-24-011806.txt ( ) — 3820KB
• apre-20240630.xsd (EX-101.SCH) — 25KB
• apre-20240630_cal.xml (EX-101.CAL) — 28KB
• apre-20240630_def.xml (EX-101.DEF) — 91KB
• apre-20240630_lab.xml (EX-101.LAB) — 228KB
• apre-20240630_pre.xml (EX-101.PRE) — 152KB
• apre-20240630x10q_htm.xml (XML) — 293KB

: FINANCIAL INFORMATION

PART I : FINANCIAL INFORMATION 5

Financial Statements

Item 1. Financial Statements 5

Management's Discussion and Analysis of Financial Condition and Results of Operations

Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations 16

Quantitative and Qualitative Disclosures About Market Risk

Item 3. Quantitative and Qualitative Disclosures About Market Risk 28

Controls and Procedures

Item 4. Controls and Procedures 28

: OTHER INFORMATION

PART II : OTHER INFORMATION 29

Legal Proceedings

Item 1. Legal Proceedings 29

Risk Factors

Item 1A. Risk Factors 29

Unregistered Sales of Equity Securities and Use of Proceeds

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds 87

Defaults Upon Senior Securities

Item 3. Defaults Upon Senior Securities 88

Mine Safety Disclosures

Item 4. Mine Safety Disclosures 88

Other Information

Item 5. Other Information 88

Exhibits

Item 6. Exhibits 89 2 Table of Contents SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS This Quarterly Report on Form 10-Q includes statements that are, or may be deemed, "forward-looking statements." In some cases, these forward-looking statements can be identified by the use of forward-looking terminology, including the terms "believes," "estimates," "anticipates," "expects," "plans," "intends," "may," "designed," "would," "could," "might," "will," "should," "approximately" or, in each case, their negative or other variations thereon or comparable terminology, although not all forward-looking statements contain these words. They appear in a number of places throughout this Quarterly Report on Form 10-Q and include statements regarding our current intentions, beliefs, projections, outlook, analyses or current expectations concerning, among other things, our ongoing and planned clinical trials, including for ATRN-119, our ongoing and planned IND-enabling studies, including for APR-1051, our ongoing and planned development, prospects for commercialization, and market uptake of our potential product candidates, the strength and breadth of our intellectual property, the timing of and our ability to make regulatory filings and obtain and maintain regulatory approvals for our product candidates, the legal and regulatory landscape impacting our business, the degree of clinical utility of our product candidates, particularly in specific patient populations, expectations regarding clinical trial data, our development and validation of manufacturing capabilities, our results of operations, financial condition, liquidity, prospects, growth and strategies, the length of time that we will be able to continue to fund our operating expenses and capital expenditures, our expected financing needs and sources of financing, the industry in which we operate and the trends that may affect the industry or us. By their nature, forward-looking statements involve risks and uncert

– Financial Information

Part I – Financial Information

Financial Statements

Item 1. Financial Statements Aprea Therapeutics, Inc. Condensed Consolidated Balance Sheets (Unaudited) June 30, December 31, 2024 2023 Assets Current assets: Cash and cash equivalents $ 28,694,694 $ 21,606,820 Prepaid expenses and other current assets 865,092 914,275 Total current assets 29,559,786 22,521,095 Property and equipment, net 92,379 88,362 Restricted cash 41,260 40,717 Other noncurrent assets 271,162 — Total assets $ 29,964,587 $ 22,650,174 Liabilities and Stockholders' Equity Current liabilities: Accounts payable $ 964,327 $ 1,670,369 Accrued expenses 2,079,163 2,186,262 Deferred grant revenue 50,739 528,974 Total current liabilities 3,094,229 4,385,605 Commitments and contingencies (Note 7) Series A convertible preferred stock, $ 0.001 par value, 40,000,000 shares authorized; 56,227 shares issued and outstanding at June 30, 2024 and December 31, 2023. 1,311,063 1,311,063 Stockholders' equity: Common stock, $ 0.001 par value, 400,000,000 shares authorized, 5,430,215 and 3,736,673 shares issued and outstanding at June 30, 2024 and December 31, 2023, respectively. 5,430 3,736 Additional paid-in capital 350,545,473 335,644,204 Accumulated other comprehensive loss ( 10,628,304 ) ( 10,611,273 ) Accumulated deficit ( 314,363,304 ) ( 308,083,161 ) Total stockholders' equity 25,559,295 16,953,506 Total liabilities and stockholders' equity $ 29,964,587 $ 22,650,174 See accompanying notes to unaudited condensed consolidated financial statements. 5 Table of Contents Aprea Therapeutics, Inc. Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited) Three Months Ended June 30, Six Months Ended June 30, 2024 2023 2024 2023 Grant revenue $ 561,574 $ 249,688 $ 942,143 $ 249,688 Operating expenses: Research and development 2,557,679 2,202,657 4,158,052 3,459,199 General and administrat

View Full Filing

View this 10-Q filing on SEC EDGAR